A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label study designed to determine the recommended Phase 2 dose (RPTD) and
evaluate the safety and pharmacokinetics of ABT-806 in subjects with advanced solid tumors.